Stock price when the opinion was issued
(A Top Pick Dec 18/19, Down 13%) This got hit like many Japanese stocks this year. It has rallied, but still not back to levels a year ago. It boast solid free cash-flow growth. This will benefit as vaccines roll-out. It's more specialized than, say, Magna. Pays a 2% dividend and boasts solid free cash-flow growth. However the rising Yen will not benefit Topre.
Tokyo exchange so we don't track.